gilead.comGilead Sciences, Inc.

Sorry, your browser does not support JavaScript! For the latest updates on our ongoing response to COVID-19, please click here . × Medicine Questions Investors Contact Global Operations North America Canada Mexico USA South America Argentina Brazil Asia China Hong Kong India Japan Korea Singapore Taiwan Middle East United Arab Emirates Africa South Africa Australia Australia New Zealand Europe Austria Belgium Luxembourg Czech Republic & Slovakia Denmark Finland France Germany Greece Iceland Ireland Israel Italy Netherlands Norway Poland & The Baltics Portugal Russia Spain Sweden Switzerland Turkey United Kingdom Our Purpose Mission and Core Values Partnerships and Community Giving Sustainability Advancing Global Health Medication Access About Leadership How We Operate Ethics and Code of Conduct U.S. Locations Science & Medicine Medicines Pipeline Research News and Press Newsroom Stories Company Statements Events Annual Report Careers Now Hiring Culture Diversity & Inclusion Benefits Internships Utility Privacy Statements Terms Of Use Social Media Guidelines EU Data Disclosure Sitemap BACK TO MAIN MENU Partnerships and Community COMPASS Initiative Gilead Lift Gilead HIV Age Positively TRANScend HepConnect BACK TO MAIN MENU Giving What We Fund Funding Requests Gilead Foundation Gilead Public Health Award BACK TO MAIN MENU Sustainability Our Business Is Sustainable Performance Reporting U.N. Global Compact U.N. Sustainable Development Goals BACK TO MAIN MENU Advancing Global Health HCV Elimination COVID-19 BACK TO MAIN MENU Medication Access U.S. Patient Access Disaster Product Replacement Global Access Authorized Distributors BACK TO MAIN MENU How We Operate Governance Transparency BACK TO MAIN MENU Ethics and Code of Conduct Policies Disclosures Anti-Counterfeiting Consumer Product Safety Supplier Information Anti-Bribery and Anti-Corruption Policy Political Contributions BACK TO MAIN MENU Research Compassionate Use Investigator-Sponsored Research Clinical Trials Transparency & Data Sharing Policy BACK TO MAIN MENU Newsroom Press Releases Press FAQS BACK TO MAIN MENU Company Statements Gilead Statement on Complaint Against Federal Government in The Court of Federal Claims Gilead Sciences Statement on Data From Remdesivir Study in Patients With Severe COVID-19 in China Gilead Sciences Response to Médecins Sans Frontières Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation Gilead Sciences Statement on Ensuring Continued Supply of HIV Medicine Amid Coronavirus Outbreak Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials Gilead Statement on U.S. Patent and Trademark Office Decision to Deny Request for Inter Partes Review of HIV PrEP Patents Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV) Gilead Statement on Commitment to Advancing Descovy for PrEP™ Study in Cisgender Women & Adolescent Females Gilead Statement on U.S. Government Complaint Regarding HIV PrEP and PEP Patents Petitions to US Patent and Trademark Office on HIV PrEP Patents Gilead Sciences Statement on U.S. Preventive Services Task Force 'A' Recommendation for PrEP as an HIV Prevention Strategy Grants for SCLAN Authorized Generics For HCV Discount For Ambisome Gilead 2017 Year in Review 100 Corporate Equality Score Emergency Disaster Response Gilead Year in Review 2016 Top Corporate Philanthropist HIV Medicines Reach 10 Million People Discover Study Of FTAF For PrEP Corporate Responsibility Report 2015 Gilead Supports PrEP Education Corporate Contributions Report Celebrating Transgender Awareness Week Kite Pharma Harnessing The Immune System BACK TO MAIN MENU Annual Report Year in Review 2018 BACK TO MAIN MENU Privacy Statements Cookie Statement Website Privacy Statement Privacy Shield Covered Entities BACK TO MAIN MENU Social Media Guidelines Linkedin Guidelines Twitter Guidelines BACK TO MAIN MENU North America Canada Mexico USA South America Argentina Brazil Asia China Hong Kong India Japan Korea Singapore Taiwan Middle East United Arab Emirates Africa South Africa Australia Australia New Zealand Europe Austria Belgium Luxembourg Czech Republic & Slovakia Denmark Finland France Germany Greece Iceland Ireland Israel Italy Netherlands Norway Poland & The Baltics Portugal Russia Spain Sweden Switzerland Turkey United Kingdom BACK TO MAIN MENU Contact Request Medicines Information Information for Suppliers Partnership Request Medicine Questions Investors Contact Global Operations Toggle Inner Dropdown BACK TO MAIN MENU Google.com Addressing the COVID-19 Pandemic. An update from our Chairman & CEO Daniel O’Day about clinical trials for our investigational treatment Read the Letter Together, we’re creating what’s possible. From science to community outreach, we’re committed to making a healthier world. Learn how Tackling Disparities. Gilead launches the COMPASS Initiative™ to help address the HIV/AIDS epidemic in the Southern United States. Gilead COMPASS Initiative Supporting Elimination Efforts. With the emergence of new therapies that have transformed chronic HCV treatment, it is now possible to eliminate the disease in certain populations. Learn more Global Access. We strive to help improve the lives of people with life-threatening illnesses around the world by giving them access to the medicine they need. We’re Advancing Global Health At Gilead, we strive to transform and simplify care for people with life-threatening diseases around the world. Our Mission Work with us. We’re Hiring News April 21, 2020 Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies Focused on Natural Killer (NK) Cells April 16, 2020 Gilead Sciences to Release First Quarter 2020 Financial Results on Thursday, April 30, 2020 Social © 2020 All rights reserved. AREAS OF INTEREST Partnerships and Community Pipeline Medicines Job Search INFORMATION Contact Us Press Room Investor Calls Sitemap LEGAL Privacy Policy Terms of Use EU Data Disclosure Social Media Guidelines Modern Slavery Act Statement FOLLOW US Headline _ Close × Intersititial body copy Ok Cancel...